摘要
目的观察化瘀祛痰颗粒对痰浊血瘀型急性冠脉综合征(ACS)经皮冠状动脉介入治疗(PIC)术后患者血小板功能及预后的影响。方法将440例痰浊血瘀型ACS行PCI术后患者按照随机数字表法分为2组,治疗组220例在西医常规治疗基础上联合化瘀祛痰颗粒治疗,对照组220例在西医常规治疗基础上联合安慰剂治疗。2组均治疗30 d,比较2组治疗前后血小板聚集率变化情况,包括花生四烯酸途径(AA)及二磷酸腺苷途径(ADP),比较2组治疗期间心脑血管不良事件的发生情况,包括全因死亡、心肌梗死、卒中及严重出血。结果 2组治疗后血小板聚集率AA及ADP与本组治疗前比较均降低(P<0.05),且治疗组治疗后血小板聚集率AA及ADP水平均低于对照组(P<0.05)。治疗组心肌梗死的发生率1.4%(3/220),总不良事件总发生率3.6%(8/220),对照组心肌梗死的发生率4.5%(10/220),总不良事件总发生率7.7%(17/220),治疗组心肌梗死及总不良事件发生情况均少于对照组(P<0.05)。结论化瘀祛痰颗粒防治ACS患者PCI术后临床疗效确切,可明显改善血小板功能,进一步降低血小板活性,降低心肌梗死发生率,降低心脑血管不良事件的发生。
Objective To observe the effect of Resolving stasis eliminating on platelet function and prognosis in patients with acute coronary syndrome( ACS) of phlegm and blood stasis type after percutaneous coronary intervention( PIC). Method: A total of 440 patients with ACS of phlegm and blood stasis type after percutaneous coronary intervention( PCI) were divided into two groups according to the random number table method. The treatment group were treated with Resolving stasis eliminating on the basis of routine western medicine treatment( n = 220),and the control group were treated with placebo on the basis of routine western medicine treatment( n = 220). Both groups were treated for 30 days. The changes of platelet aggregation rate before and after treatment were compared between the two groups,including arachidonic acid pathway( AA) and adenosine diphosphate pathway( ADP). The incidence of cardiovascular and cerebrovascular adverse events during treatment was compared between the two groups,including all-cause death,myocardial infarction,stroke and severe bleeding. Result The platelet aggregation rates of AA and ADP in the two groups after treatment were lower than those before treatment( P < 0. 05),and the levels of AA and ADP in the treatment group after treatment were lower than those in the control group( P < 0. 05). The incidence of myocardial infarction in the treatment group was 1. 4%( 3/220),and the total incidence of adverse events was 3. 6%( 8/220). The incidence of myocardial infarction in the control group was 4. 5%( 10/220),and the total incidence of adverse events was 7. 7%( 17/220). The incidence of myocardial infarction and total adverse events in the treatment group were less than those in the control group( P < 0. 05). Conclusion Resolving stasis eliminating has definite clinical efficacy in the prevention and treatment of ACS patients after PCI,which can significantly improve platelet function,further reduce platelet activity,reduce the incidence of myocardial infarction,and reduce the incidence of
作者
于乐
陈韦
齐静
周鑫
YU Le;CHEN Wei;Qi Jing(Department of Cardiology,Affiliated Hospital of Liaoning University of Chinese Medicine,Liaoning,Shenyang 110032)
出处
《河北中医》
2020年第11期1637-1640,共4页
Hebei Journal of Traditional Chinese Medicine
基金
辽宁省自然科学基金项目(20180550907)。
关键词
冠状动脉疾病
经皮冠状动脉介入治疗
血小板
中药疗法
Resolving stasis eliminating phlegm
acute coronary syndrome
turbid phlegm and blood stasis syndrome
platelet
